Survodutide vs Retatrutide: Dual vs Triple Agonist

TL;DR

- Survodutide vs retatrutide is a comparison of a dual agonist against a triple agonist. Survodutide targets GLP-1 and glucagon receptors; retatrutide targets GLP-1, GIP, and glucagon receptors. Both are investigational and not approved. - In a phase 2 trial, survodutide reached a mean weight change of about 14.9 percent at 46 weeks in the 4.8 mg group, and about 18.7 percent among participants who reached and stayed on that dose (le Roux et al., 2024, Lancet Diabetes and Endocrinology). - In a phase 2 trial, retatrutide reached up to about 24.2 percent mean weight loss at the 12 mg dose by 48 weeks (Jastreboff et al., 2023, New England Journal of Medicine). - Both compounds report gastrointestinal side effects such as nausea, common to the GLP-1 receptor class. - Neither has completed the phase 3 program needed for regulatory approval, so the weight figures below come from phase 2 research.

What is the core difference between survodutide and retatrutide?

Survodutide hits two receptors; retatrutide hits three. Survodutide is a dual agonist that activates the GLP-1 receptor and the glucagon receptor. Retatrutide is a triple agonist that activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. The extra GIP arm is the main structural distinction between the two molecules.

Both build on the same idea: combine gut and pancreatic hormone signaling into one molecule to influence appetite, energy use, and metabolism at once. Survodutide leans on the glucagon receptor to raise energy expenditure alongside GLP-1 driven appetite reduction. Retatrutide adds GIP receptor activity on top of that same dual base.

Neither is a finished, approved product. Both are still moving through clinical research, so the comparison here is between two sets of trial results, not two shelf products.

What receptors does each compound target?

Survodutide targets GLP-1 and glucagon; retatrutide targets GLP-1, GIP, and glucagon. The table below lays out the mechanism side by side.

The GLP-1 receptor is the shared anchor. Semaglutide, a single GLP-1 agonist, produced about 15 percent mean weight loss in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), which is the baseline the multi-receptor agonists aim to improve on.

How much weight loss did each report in trials?

Retatrutide reported a higher peak figure than survodutide in phase 2 research, but the two were studied in separate trials, so these are not direct head-to-head numbers and should not be read as a like-for-like ranking. In the retatrutide phase 2 trial, participants reached up to about 24.2 percent mean weight loss at the 12 mg dose by 48 weeks (Jastreboff et al., 2023, New England Journal of Medicine). In the survodutide phase 2 dose-finding trial, the 4.8 mg group reached a mean weight change of about 14.9 percent at 46 weeks, rising to about 18.7 percent among participants who reached and stayed on the 4.8 mg dose (le Roux et al., 2024, Lancet Diabetes and Endocrinology).

Cross-trial numbers should be read with care. Trial populations, dose schedules, and durations differ, so the only fair statement is what each study reported on its own terms. These are research-reported figures, not outcomes promised to any individual.

Survodutide has also been studied beyond weight, including in metabolic dysfunction associated steatohepatitis (MASH), reflecting interest in its glucagon-driven effect on liver fat. In a separate phase 2 MASH trial, a larger share of participants on survodutide reached resolution of the condition without worsening fibrosis than on placebo (Sanyal et al., 2024, New England Journal of Medicine).

What are the side-effect profiles?

Both compounds report gastrointestinal side effects, which are typical for the GLP-1 receptor class. Nausea, vomiting, diarrhea, and reduced appetite are the most commonly reported events in this drug class. Retatrutide reported these effects in its phase 2 trial (Jastreboff et al., 2023, NEJM), and survodutide reported a similar gastrointestinal pattern in its phase 2 dose-finding trial (le Roux et al., 2024, Lancet Diabetes and Endocrinology).

Gastrointestinal effects are well documented across GLP-1 based therapy more broadly, including the STEP 1 semaglutide trial (Wilding et al., 2021, NEJM), which gives a sense of how common these symptoms are for the receptor class both compounds share.

Because both agonists are still investigational, the full long-term safety picture is not settled. Phase 3 data would be needed before any complete side-effect profile could be described with confidence.

Which one is further along in research?

Neither has completed the full approval path, and both remain investigational. Both figures on this page come from published phase 2 work: retatrutide in obesity (Jastreboff et al., 2023, NEJM) and survodutide in obesity (le Roux et al., 2024, Lancet Diabetes and Endocrinology). Survodutide has additional published trial work in MASH, extending its interest beyond body weight (Sanyal et al., 2024, NEJM), and has since moved into a phase 3 obesity program.

One point that applies to the whole GLP-1 class: weight tends to return after therapy stops. Studies of related agents reported meaningful regain after withdrawal (Aronne et al., 2024, JAMA; Wilding et al., 2022, Diabetes Obesity and Metabolism). Nothing published so far suggests survodutide or retatrutide is exempt from this pattern, though neither has long-term withdrawal data at the same depth.